Quad Technologies Announces Poster Presentation at the 58th American Society of Hematology Annual Meeting

Poster presentation includes data featuring activation and expansion of T cells using a novel phase change hydrogel

WOBURN, Mass.--()--An abstract from Quad Technologies (”Quad”) has been accepted for presentation at the 58th annual American Society of Hematology meeting in San Diego, CA on December 3-6, 2016. The abstract is published on the ASH website at http://www.hematology.org/.

In collaboration with an external partner focused on CAR-T cancer immunotherapy, the focus of the poster presentation is the use of a phase change hydrogel substrate to activate and expand T cells and its subsequent influence on CD8+ cells expressing central memory and naïve phenotypic markers. The research outcome presents a T cell activation and expansion methodology that provides novel bioprocessing solutions to address cell therapy manufacturing challenges associated with magnetic de-beading and other workflow inefficiencies present today.

Andrew Ball, Ph.D leader of the study and Vice President of R&D at Quad notes, “We are excited that this abstract was accepted and will be presented at ASH 2016. The work highlights the use of a differentiated approach to activate, expand and preferentially modulate phenotypic marker expression in T lymphocytes. We look forward to advancing this research in areas that can best support clinical cell therapy manufacturing workflows.”

Poster Presentation

Title: Novel Phase-Change Hydrogel Substrate for T Cell Activation Promotes Increased Expansion of CD8+ Cells Expressing Central Memory and Naive Phenotype Markers (Abstract #3368)
Session Name: 711. Cell Collection and Processing: Poster II
Session Date: Sunday, December 4, 2016
Session Time: 6:00 PM-8:00 PM (San Diego Convention Center Hall GH)

About Quad Technologies

Quad Technologies is a developer of a differentiated dissolvable hydrogel used for cell separation and expansion in research and clinical applications. With a customer-centric product driven business model, the company is committed to addressing the needs of researchers and clinical bioprocess developers working in cell based therapeutics. www.quadtechnologies.com

Contacts

Quad Technologies
Kiara Biagioni, 339-927-9663
Director of Marketing
kbiagioni@quadtechnologies.com

Contacts

Quad Technologies
Kiara Biagioni, 339-927-9663
Director of Marketing
kbiagioni@quadtechnologies.com